Neoadjuvant Systemic Therapy Promising for Resectable Colorectal Peritoneal Metastases medscape.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from medscape.com Daily Mail and Mail on Sunday newspapers.
Share this article
Share this article
HORSHAM, Pa., May 21, 2021 /PRNewswire/ The Janssen Pharmaceutical Companies of Johnson & Johnson announced today the U.S. Food and Drug Administration (FDA) has granted the accelerated approval of RYBREVANT
TM (amivantamab-vmjw) for the treatment of adult patients with locally advanced or metastatic non-small cell lung cancer (NSCLC) with epidermal growth factor receptor (EGFR) exon 20 insertion mutations, as detected by an FDA-approved test, whose disease has progressed on or after platinum-based chemotherapy.
1 RYBREVANT
TM is the first fully-human, bispecific antibody approved for the treatment of patients with NSCLC that targets EGFR exon 20 insertion mutations, which are the third most prevalent activating EGFR mutation.
Perlmutter Cancer Center at NYU Langone Health Joins Call For Urgent Action To Get Cancer-Preventing HPV Vaccination Back On Track prnewswire.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from prnewswire.com Daily Mail and Mail on Sunday newspapers.
E-Mail
IMAGE: HPV infection causes cells to undergo changes. If not treated these cells can, over time, become cancer cells. view more
Credit: National Cancer Institute
Today, doctors and scientists across America at National Cancer Institute (NCI)-designated cancer centers and other organizations issued a joint statement urging the nation s health care systems, physicians, parents and children, and young adults to get the human papillomavirus (HPV) vaccination back on track.
Dramatic drops in annual well visits and immunizations during the COVID-19 pandemic have caused a significant vaccination gap and lag in vital preventive services among U.S. children and adolescents especially for the HPV vaccine. The pandemic also has exacerbated health disparities, leaving Black, Indigenous and other people of color; rural; and sexual minority adolescents at even greater risk for missed doses of this cancer prevention vaccine.
Share this article
Share this article
NEW YORK, May 19, 2021 /PRNewswire/ Cancer drugs capable of weakening the body s immune defenses are no more likely to increase the risk of Covid-19 infection or death than breast cancer therapies that do not undermine the immune system, a new study shows. Researchers say the results challenge initial concerns that such treatments, which poison cancer cells, were too dangerous to continue during the pandemic.
Led by researchers at NYU Langone Health and its Perlmutter Cancer Center, the new investigation involving over 3,000 women treated for breast cancer at the height of the pandemic in New York City showed that only 64, or 2 percent, contracted the virus. Of this group, 10 died from COVID-19, a number the study authors say is low and expected for this age group, regardless of cancer.